On April 14, 2020, Yiling Pharmaceutical announced that Yiling Pharmaceutical 
and its subsidiary Beijing Yiling Pharmaceutical had received the approval 
document of drug supplement application concerning the application for new 
indications of Lianhua Qingwen capsules and Lianhua Qingwen granules issued by 
State Drug Administration. Lianhua Qingwen capsule and Lianhua Qingwen granules 
were approved to add "functional indications" to the originally approved 
indications: "In the conventional treatment of novel coronavirus pneumonia, it 
can be used for a light, common type of fever, cough, and fatigue", "Usage and 
dosage" increased "COVID-19 light, normal treatment for 7-10 days" and so on. 

In this domestic epidemic, Lianhua Qingwen capsules (granules) became the most 
frequently recommended Chinese patent medicine for COVID 19. In the fourth to 
the seventh edition of the novel pneumonia diagnosis and treatment scheme 
infected by coronavirus published by the state health commission and the state 
administration of traditional Chinese medicine, it is recommended to take the 
Chinese patent medicine Lianhua Qingwen capsule (granule) for the prevention 
and treatment of patients with fatigue and fever during the medical observation 
period. 

Photo - https://photos.prnasia.com/prnh/20200414/2776417-1 

The efficacy of the Lianhua Qingwen capsule (granule) in the treatment of 
COVID-19 has been confirmed by basic experiments and clinical studies. Zhong 
Nanshan's team recently published a paper entitled "The antiviral and 
anti-inflammatory effect of the antipyretic plague on novel coronavirus" in the 
international journal "Pharmacology Research", which was the first basic 
research article of effective Chinese patent medicine against SARS-Cov-2. In 
this study, it was found that Lianhua Qingwen could significantly inhibit the 
replication of novel coronavirus in cells, and the expression of virus 
particles in cells was significantly reduced after the treatment of 
coronavirus. 

It is reported that this approval is in the originally approved indications 
based on the addition of the "COVID 19 light, ordinary type" of the new 
indications. At the same time, the new batch of prescription drug 
specifications did not deny the original non-prescription drug positioning. 

Up to now, Lianhua Qingwen capsules have been registered in Hong Kong (SAR of 
China), Macao (SAR of China), Brazil, Indonesia, Canada, Mozambique, Romania 
and other places as "Chinese patent medicine", "medicine", "plant medicine" and 
"natural health products", and have been approved for marketing. 

SOURCE Shijiazhuang Yiling Pharmaceutical Co, Ltd.